ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 145 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $370 | -34.0% | 54,100 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $561 | -53.6% | 54,100 | -63.9% | 0.00% | 0.0% |
| Q1 2023 | $1,209 | +111.0% | 149,700 | +311.3% | 0.00% | -33.3% |
| Q4 2022 | $573 | -99.8% | 36,400 | +82.9% | 0.00% | +200.0% |
| Q3 2022 | $313,000 | +25.7% | 19,900 | +11.2% | 0.00% | 0.0% |
| Q2 2022 | $249,000 | +107.5% | 17,900 | +167.2% | 0.00% | – |
| Q3 2021 | $120,000 | -59.5% | 6,700 | -60.4% | 0.00% | -100.0% |
| Q2 2021 | $296,000 | -52.9% | 16,900 | -19.9% | 0.00% | -66.7% |
| Q1 2017 | $629,000 | +203.9% | 21,100 | +160.5% | 0.00% | +200.0% |
| Q3 2016 | $207,000 | +276.4% | 8,100 | +170.0% | 0.00% | – |
| Q2 2016 | $55,000 | +52.8% | 3,000 | +57.9% | 0.00% | – |
| Q1 2016 | $36,000 | -29.4% | 1,900 | 0.0% | 0.00% | – |
| Q4 2015 | $51,000 | – | 1,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |